{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T13:28:11Z","timestamp":1793798891473,"version":"4.6.1"},"reference-count":86,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["medical-hypotheses.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.mehy.2013.11.017","type":"journal-article","created":{"date-parts":[[2013,11,22]],"date-time":"2013-11-22T00:45:33Z","timestamp":1385081133000},"page":"105-110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Therapeutic potential of agomelatine in epilepsy and epileptic complications"],"prefix":"10.1016","volume":"82","author":[{"given":"P.V.","family":"Vimala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.S.","family":"Bhutada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"46","key":"10.1016\/j.mehy.2013.11.017_b0005","first-page":"1133","article-title":"Psychological distress, comorbidities and health behaviors among U.S. adults with seizures: results from the 2002 National Health Interview Survey","volume":"2005","author":"Strine","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.mehy.2013.11.017_b0010","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.yebeh.2003.11.012","article-title":"Do seizures cause irreversible cognitive damage? Evidence from animal studies","volume":"5","author":"Majak","year":"2004","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.mehy.2013.11.017_b0015","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.yebeh.2005.08.005","article-title":"Models of epilepsy in the developing and adult brain: implications for neuroprotection","volume":"7","author":"Stafstrom","year":"2005","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.mehy.2013.11.017_b0020","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ejphar.2011.11.010","article-title":"Age dependent learning and memory deficit in pentylenetetrazole kindled mice","volume":"674","author":"Mishra","year":"2012","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.mehy.2013.11.017_b0025","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.yebeh.2009.03.020","article-title":"The psychosocial impact of epilepsy in adults with an intellectual disability","volume":"15","author":"Kerr","year":"2009","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.mehy.2013.11.017_b0030","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0920-1211(99)00036-4","article-title":"The relationship between memory performance, perceived cognitive function, and mood in patients with epilepsy","volume":"37","author":"Elixhausera","year":"1999","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.mehy.2013.11.017_b0035","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.seizure.2006.02.011","article-title":"Cognitive rehabilitation of memory problems in patients with epilepsy","volume":"15","author":"Ponds","year":"2006","journal-title":"Seizure"},{"key":"10.1016\/j.mehy.2013.11.017_b0040","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.yebeh.2003.07.004","article-title":"Epilepsy and cognition","volume":"4","author":"Motamedi","year":"2003","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.mehy.2013.11.017_b0045","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.seizure.2010.12.006","article-title":"Effect of lamotrigine, oxcarbazepine and topiramate on cognitive functions and oxidative stress in PTZ-kindled mice","volume":"20","author":"Agarwal","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.mehy.2013.11.017_b0050","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.yebeh.2012.10.013","article-title":"Functional MRI and structural MRI as tools for understanding comorbid conditions in children with epilepsy","volume":"26","author":"McDonald","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.mehy.2013.11.017_b0055","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.biopsych.2009.11.008","article-title":"Hippocampal synaptic plasticity, memory, and epilepsy: effects of long-term valproic acid treatment","volume":"67","author":"Sgobio","year":"2010","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.mehy.2013.11.017_b0060","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.yebeh.2009.07.031","article-title":"Upregulation of 5-HT2C receptors in hippocampus of pilocarpine-induced epileptic rats: antagonism by Bacopa monnieri","volume":"16","author":"Krishnakumar","year":"2009","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.mehy.2013.11.017_b0065","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.seizure.2012.09.003","article-title":"Oxidative stress in patients with epilepsy is independent of antiepileptic drugs","volume":"21","author":"Menon","year":"2012","journal-title":"Seizure"},{"key":"10.1016\/j.mehy.2013.11.017_b0070","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S1059-1311(97)80022-2","article-title":"Piracetam prevents pentylenetetrazole kindling-induced neuronal loss and learning deficits","volume":"6","author":"Pohle","year":"1997","journal-title":"Seizure"},{"key":"10.1016\/j.mehy.2013.11.017_b0075","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.yebeh.2003.10.003","article-title":"Psychiatric comorbidity, health, and function in epilepsy","volume":"4","author":"Gilliam","year":"2003","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.mehy.2013.11.017_b0080","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.nbd.2009.11.001","article-title":"Comorbidity between epilepsy and depression: role of hippocampal interleukin-1\u03b2","volume":"37","author":"Mazarati","year":"2010","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.mehy.2013.11.017_b0085","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bcp.2012.08.016","article-title":"Rhythm and blues: animal models of epilepsy and depression comorbidity","volume":"85","author":"Epps","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.mehy.2013.11.017_b0090","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.yebeh.2012.01.007","article-title":"Depression and epilepsy: epidemiologic and neurobiologic perspectives that may explain their high comorbid occurrence","volume":"24","author":"Kanner","year":"2012","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.mehy.2013.11.017_b0095","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.yebeh.2003.08.020","article-title":"Common pathogenic mechanisms between depression and epilepsy: an experimental perspective","volume":"4","author":"Jobe","year":"2003","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.mehy.2013.11.017_b0100","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0006-3223(03)00469-4","article-title":"Depression in epilepsy: prevalence, clinical semiology, pathogenic mechanisms and treatment","volume":"54","author":"Kanner","year":"2003","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.mehy.2013.11.017_b0105","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.yebeh.2009.02.034","article-title":"Psychiatric issues in epilepsy: the complex relation of mood, anxiety disorders and epilepsy","volume":"15","author":"Kanner","year":"2009","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.mehy.2013.11.017_b0110","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neuropharm.2011.07.036","article-title":"Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders","volume":"62","author":"Sanacora","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.mehy.2013.11.017_b0115","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.expneurol.2011.05.023","article-title":"Depression, stress, epilepsy and adult neurogenesis","volume":"233","author":"Danzer","year":"2012","journal-title":"Exp Neurol"},{"key":"10.1016\/j.mehy.2013.11.017_b0120","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.neuropharm.2011.08.020","article-title":"Circadian rhythms and depression: human psychopathology and animal models","volume":"62","author":"Schor","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.mehy.2013.11.017_b0125","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.yebeh.2011.12.009","article-title":"Impact of the chronic use of benzodiazepines prescribed for seizure control on the anxiety levels of patients with epilepsy","volume":"23","author":"Pizzol","year":"2012","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.mehy.2013.11.017_b0130","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.yebeh.2005.05.014","article-title":"Anxiety in patients with epilepsy: systematic review and suggestions for clinical management","volume":"7","author":"Beyenburg","year":"2005","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.mehy.2013.11.017_b0135","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.yebeh.2005.02.017","article-title":"Differentiating anxiety and depression symptoms in patients with partial epilepsy","volume":"6","author":"Cramer","year":"2005","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.mehy.2013.11.017_b0140","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.yebeh.2005.12.015","article-title":"A comparison of the circadian rhythms and the levels of melatonin in patients with diurnal and nocturnal complex partial seizures","volume":"8","author":"Yalyn","year":"2006","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.mehy.2013.11.017_b0145","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/0920-1211(90)90056-2","article-title":"Sleep patterns in patients with late onset partial epilepsy receiving chronic carbamazepine (CBZ) therapy","volume":"7","author":"Manni","year":"1990","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.mehy.2013.11.017_b0150","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.yebeh.2011.03.005","article-title":"Sleep characteristics of patients with epilepsy with pure sleep-related seizures","volume":"21","author":"Ekizoglu","year":"2011","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.mehy.2013.11.017_b0155","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.sleep.2010.01.012","article-title":"Sleep and epilepsy in children and adolescents","volume":"11","author":"Kothare","year":"2010","journal-title":"Sleep Med"},{"issue":"Suppl. 1","key":"10.1016\/j.mehy.2013.11.017_b0160","first-page":"142","article-title":"Effects of nootropic drugs on pentylenetetrazole kindling in rats","volume":"3","author":"Genkova-Papazova","year":"1992","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.mehy.2013.11.017_b0165","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1532-0456(02)00037-6","article-title":"Attenuating effects of melatonin on pilocarpine-induced seizures in rats","volume":"131","author":"Costa-Lotufo","year":"2002","journal-title":"Comp Biochem Physiol C Toxicol Pharmacol"},{"key":"10.1016\/j.mehy.2013.11.017_b0170","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0924-977X(98)00022-4","article-title":"Influence of melatonin upon the protective action of conventional antiepileptic drugs against maximal electroshock in mice","volume":"9","author":"Borowicz","year":"1999","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.mehy.2013.11.017_b0175","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.yebeh.2011.01.018","article-title":"Melatonin administration after pilocarpine-inducedstatus epilepticus: a new way to prevent or attenuate post lesion epilepsy?","volume":"20","author":"Lima","year":"2011","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.mehy.2013.11.017_b0180","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.eplepsyres.2005.09.057","article-title":"Involvement of nitric oxide pathway in the acute anticonvulsant effect of melatonin in mice","volume":"68","author":"Firouz-Abadi","year":"2006","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.mehy.2013.11.017_b0185","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0028-3908(81)90043-5","article-title":"The anticonvulsant melatonin on kindled properties of seizures in rats","volume":"20","author":"Albertson","year":"1981","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.mehy.2013.11.017_b0190","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.yebeh.2011.07.002","article-title":"The interaction of melatonin and agmatine on pentylenetetrazole-induced seizure threshold in mice","volume":"22","author":"Moezi","year":"2011","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.mehy.2013.11.017_b0195","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.yebeh.2013.01.009","article-title":"Prophylactic treatment with melatonin after status epilepticus: effects on epileptogenesis, neuronal damage and behavioral changes in a kainate model of temporal lobe epilepsy","volume":"27","author":"Tchekalarova","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.mehy.2013.11.017_b0200","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1734-1140(12)70769-7","article-title":"Influence of calcium channel blockers on anticonvulsant and antinociceptive activities of valproic acid in pentylenetetrazole-kindled mice","volume":"64","author":"El-Azab","year":"2012","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.mehy.2013.11.017_b0205","first-page":"126","article-title":"Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors","volume":"29","author":"Bourin","year":"2004","journal-title":"J Psychiatry Neurosci"},{"key":"10.1016\/j.mehy.2013.11.017_b0210","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.neuropharm.2010.05.008","article-title":"Effect of agomelatine and its interaction with the daily corticosterone rhythm on progenitor cell proliferation in the dentate gyrus of the adult rat","volume":"59","author":"AlAhmed","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.mehy.2013.11.017_b0215","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.sleep.2007.01.011","article-title":"Non-REM sleep instability in patients with major depressive disorder: subjective improvement and improvement of non-REM sleep instability with treatment (Agomelatine)","volume":"9","author":"Lopes","year":"2007","journal-title":"Sleep Med"},{"key":"10.1016\/j.mehy.2013.11.017_b0220","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.pbb.2011.02.015","article-title":"Memory facilitating effects of agomelatine in the novel object recognition memory paradigm in the rat","volume":"98","author":"Anglade","year":"2011","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.mehy.2013.11.017_b0225","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.yebeh.2012.04.134","article-title":"Anticonvulsant effects of agomelatine in mice","volume":"24","author":"Aguiar","year":"2012","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.mehy.2013.11.017_b0230","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0196-9781(93)90030-K","article-title":"Circadian effects of beta-endorphin, melatonin, DSIP and amphetamine on pentylenetetrazole- induced seizures","volume":"14","author":"Yehuda","year":"1993","journal-title":"Peptides"},{"key":"10.1016\/j.mehy.2013.11.017_b0235","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.mce.2012.01.004","article-title":"Melatonin membrane receptors in peripheral tissues: distribution and functions","volume":"351","author":"Slominski","year":"2012","journal-title":"Mol Cell Endocrinol"},{"issue":"Suppl. 4","key":"10.1016\/j.mehy.2013.11.017_b0240","doi-asserted-by":"crossref","first-page":"S365","DOI":"10.1016\/S0924-977X(07)70535-7","article-title":"The novel antidepressant agomelatine reduces release of glutamate and related presynaptic mechanisms in rat hippocampus","volume":"17","author":"Barbiero","year":"2007","journal-title":"Eur Neuropsychopharmacol"},{"issue":"Suppl. 3","key":"10.1016\/j.mehy.2013.11.017_b0245","doi-asserted-by":"crossref","first-page":"S441","DOI":"10.1016\/S0924-977X(09)70687-X","article-title":"Agomelatine reduces glutamate release induced by acute stress, possible synergism between melatonin and 5HT2C properties","volume":"19","author":"Mallei","year":"2009","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.mehy.2013.11.017_b0250","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejphar.2008.04.016","article-title":"Agomelatine, a melatonin receptor agonist with 5-HT2Creceptor antagonist properties, protects the developing murine white matter against excitotoxicity","volume":"588","author":"Gressens","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.mehy.2013.11.017_b0255","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.neuint.2011.03.025","article-title":"Role of oxidative stress in epileptic seizures","volume":"59","author":"Shin","year":"2011","journal-title":"Neurochem Int"},{"key":"10.1016\/j.mehy.2013.11.017_b0260","author":"Aguiar","year":"2012","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.mehy.2013.11.017_b0265","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.brainresbull.2010.09.007","article-title":"Effect of pentylenetetrazole and sound stimulation induced single and repeated convulsive seizures on the MDA, GSH and NO levels, and SOD activities in rat liver and kidney tissues","volume":"8","author":"Dillioglugila","year":"2010","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.mehy.2013.11.017_b0270","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.yhbeh.2012.02.020","article-title":"Melatonin and mitochondrial dysfunction in the central nervous system","volume":"63","author":"Cardinali","year":"2013","journal-title":"Horm Behav"},{"key":"10.1016\/j.mehy.2013.11.017_b0275","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.biopsych.2005.11.025","article-title":"Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis","volume":"59","author":"Banasr","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.mehy.2013.11.017_b0280","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2174\/157015910792246227","article-title":"A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation","volume":"8","author":"Fornaro","year":"2010","journal-title":"Curr Neuropharmacol"},{"issue":"Suppl. 4","key":"10.1016\/j.mehy.2013.11.017_b0285","doi-asserted-by":"crossref","first-page":"S350","DOI":"10.1016\/S0924-977X(08)70491-7","article-title":"Cellular and molecular mechanisms underlying increased adult hippocampal neurogenesis induced by agomelatine","volume":"18","author":"Soumier","year":"2008","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.mehy.2013.11.017_b0290","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.bbr.2010.11.045","article-title":"Agomelatine reverses the decrease in hippocampal cell survival induced by chronic mild stress","volume":"218","author":"Dagyte","year":"2011","journal-title":"Behav Brain Res"},{"issue":"Suppl. 3","key":"10.1016\/j.mehy.2013.11.017_h0440","doi-asserted-by":"crossref","first-page":"S549","DOI":"10.1016\/S0924-977X(11)70894-X","article-title":"Neuroprotective potential of agomelatine for depression in Alzheimer\u2019s disease: animal model study","volume":"21","author":"Marinescu","year":"2011","journal-title":"Eur Neuropsychopharmacol"},{"issue":"Suppl. 1","key":"10.1016\/j.mehy.2013.11.017_h0445","first-page":"1256","article-title":"The neuroprotective potentially of agomelatine \u2013 animal model study","volume":"26","year":"2011","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.mehy.2013.11.017_b0300","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1017\/S1461145708009255","article-title":"The antidepressant agomelatine blocks the adverse effects of stress on memory and enables spatial learning to rapidly increase neural cell adhesion molecule (NCAM) expression in the hippocampus of rats","volume":"3","author":"Conboy","year":"2009","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.mehy.2013.11.017_b0305","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/nrd3274","article-title":"Agomelatine, the first melatonergic antidepressant: discovery, characterization and development","volume":"9","author":"Bodinat","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"Suppl. 3","key":"10.1016\/j.mehy.2013.11.017_b0310","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0924-977X(02)80182-1","article-title":"Evidence for two components in the mechanism of action of S20098 (agomelatine) in a chronic mild stress animal model of depression","volume":"12","author":"Papp","year":"2002","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.mehy.2013.11.017_b0315","doi-asserted-by":"crossref","first-page":"S703","DOI":"10.1016\/j.euroneuro.2011.07.004","article-title":"Agomelatine: a narrative review","volume":"21","author":"Demyttenaere","year":"2011","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.mehy.2013.11.017_b0320","doi-asserted-by":"crossref","first-page":"S633","DOI":"10.1016\/S0924-977X(06)70009-8","article-title":"Major depressive disorders: clinical efficacy and tolerability of agomelatine, a new melatonergic agonist","volume":"16","author":"Montgomery","year":"2006","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.mehy.2013.11.017_b0325","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1176\/appi.neuropsych.11090216","article-title":"Agomelatine in depressive disorders: its novel mechanisms of action","volume":"24","author":"Srinivasan","year":"2012","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.mehy.2013.11.017_b0330","doi-asserted-by":"crossref","first-page":"428","DOI":"10.2174\/092986712803414277","article-title":"Emerging targets for the pharmacological treatment of depression: focus on melatonergic system","volume":"19","author":"Catena-Dell\u2019Osso","year":"2012","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.mehy.2013.11.017_b0335","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.euroneuro.2005.02.004","article-title":"Anxiolytic-like action of the antidepressant agomelatine (S 20098) after a social defeat requires the integrity of the SCN","volume":"15","author":"Tuma","year":"2005","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.mehy.2013.11.017_b0340","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.euroneuro.2005.11.007","article-title":"Effects of melatonin and agomelatine in anxiety-related procedures in rats: interaction with diazepam","volume":"16","author":"Loiseau","year":"2006","journal-title":"Eur Neuropsychopharmacol"},{"issue":"Suppl. 1","key":"10.1016\/j.mehy.2013.11.017_b0345","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0924-9338(10)70293-5","article-title":"Beneficial effects of chronic treatment with agomelatine on the anxiety- and depression-like state induced by corticosterone in C57BL\/6NTAC mice","volume":"25","author":"Rainer","year":"2010","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.mehy.2013.11.017_b0350","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1037\/a0030263","article-title":"A review of preliminary observations on agomelatine in the treatment of anxiety disorders","volume":"6","author":"Levitan","year":"2012","journal-title":"Exp Clin Psychopharmacol"},{"issue":"Suppl. 3","key":"10.1016\/j.mehy.2013.11.017_b0355","doi-asserted-by":"crossref","first-page":"S383D","DOI":"10.1016\/S0924-977X(11)70615-0","article-title":"Efficacy of the novel antidepressant agomelatine for anxiety symptoms within depression","volume":"21","author":"Stein","year":"2011","journal-title":"Eur Neuropsychopharmacol"},{"issue":"Suppl. 1","key":"10.1016\/j.mehy.2013.11.017_b0360","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0924-9338(11)71892-2","article-title":"Long-term treatment with agomelatine: prevention of relapse in patients with generalized anxiety disorder over 6 months","volume":"26","author":"Stein","year":"2011","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.mehy.2013.11.017_b0365","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0028-3908(97)00038-5","article-title":"SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist","volume":"36","author":"Kennett","year":"1997","journal-title":"Neuropharrnacology"},{"key":"10.1016\/j.mehy.2013.11.017_b0370","first-page":"65","article-title":"The effects of antidepressants on sleep in depressed patients with particular reference to trazodone in comparison to agomelatine, amitriptyline, doxepin, mianserine and mirtazapine","volume":"31","author":"Wichniak","year":"2011","journal-title":"Pol Merkur Lekarski"},{"key":"10.1016\/j.mehy.2013.11.017_b0375","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.exger.2005.08.009","article-title":"Melatonin and sleep in aging population","volume":"40","author":"Pandi-Perumal","year":"2005","journal-title":"Exp Gerontol"},{"issue":"Suppl. 1","key":"10.1016\/j.mehy.2013.11.017_b0380","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1016\/j.eurpsy.2007.01.1174","article-title":"A new pharmacological step: the melatonergic approach","volume":"22","author":"Racagni","year":"2007","journal-title":"Eur Psychiatry"},{"issue":"Suppl. 3","key":"10.1016\/j.mehy.2013.11.017_b0385","doi-asserted-by":"crossref","first-page":"S419","DOI":"10.1016\/S0924-977X(09)70650-9","article-title":"Agomelatine antidepressant: advantages over sertraline and venlafaxine in \u201cclinical effectiveness\u201d","volume":"19","author":"Kennedy","year":"2009","journal-title":"Eur Neuropsychopharmacol"},{"issue":"Suppl. 4","key":"10.1016\/j.mehy.2013.11.017_b0390","doi-asserted-by":"crossref","first-page":"S336","DOI":"10.1016\/S0924-977X(08)70468-1","article-title":"Superior antidepressant efficacy of agomelatine versus sertraline: a randomised, double-blind study","volume":"18","author":"Kasper","year":"2008","journal-title":"Eur Neuropsychopharmacol"},{"issue":"Suppl. 3","key":"10.1016\/j.mehy.2013.11.017_b0395","first-page":"S419","article-title":"Efficacy of agomelatine versus venlafaxine on subjective sleep of patients with major depressive disorder","volume":"15","author":"Guilleminault","year":"2005","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.mehy.2013.11.017_b0400","doi-asserted-by":"crossref","first-page":"S639","DOI":"10.1016\/S0924-977X(06)70010-4","article-title":"Depression and associated sleep disturbances: patient benefits with agomelatine","volume":"16","author":"Kupfer","year":"2006","journal-title":"Eur Neuropsychopharmacol"},{"issue":"Suppl. 3","key":"10.1016\/j.mehy.2013.11.017_b0405","first-page":"S660","article-title":"The benefits of agomelatine beyond antidepressant efficacy: impact on sleep","volume":"15","author":"Lam","year":"2005","journal-title":"Eur Neuropsychopharmacol"},{"issue":"Suppl. 1","key":"10.1016\/j.mehy.2013.11.017_b0410","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0924-9338(11)72325-2","article-title":"Agomelatine versus escitalopram in major depressive disorders: a randomized double-blind, long term study focusing on sleep satisfaction and emotional blunting","volume":"26","author":"Corruble","year":"2011","journal-title":"Eur Psychiatry"},{"issue":"Suppl. 3","key":"10.1016\/j.mehy.2013.11.017_b0415","first-page":"S435","article-title":"Effect of agomelatine on the sleep EEG in patients with major depressive disorder (MMD)","volume":"15","author":"Quera-Salva","year":"2005","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.mehy.2013.11.017_b0420","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.pneurobio.2009.04.007","article-title":"Bidirectional communication between sleep and circadian rhythms and its implications for depression: lessons from agomelatine","volume":"88","author":"Pandi-Perumal","year":"2009","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.mehy.2013.11.017_b0425","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.yebeh.2010.03.005","article-title":"The effects of rutin on the development of pentylenetetrazole kindling and memory retrieval in rats","volume":"18","author":"Nassiri-Asla","year":"2010","journal-title":"Epilepsy Behav"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987713005446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987713005446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T20:57:13Z","timestamp":1539032233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987713005446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":86,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0306987713005446"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2013.11.017","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic potential of agomelatine in epilepsy and epileptic complications","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2013.11.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}